Welcome to the e-CCO Library!

P338: Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Dirrenberger B.*1, Clerc-Urmès I.2, Germain A.3, Bresler L.3, Olivera P.1, Martelli L.1, Baumann C.2, Laurent V.4, Peyrin-Biroulet L.1

Created: Wednesday, 20 February 2019, 10:36 AM
P339 Assessment of DNA-thioguanine nucleotide identifies patients at risk of thiopurine-induced leukopoenia in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

X. Zhu1, K. Chao2, X. Gao2, M. Huang1, X.D. Wang1

Created: Thursday, 30 January 2020, 10:12 AM
P339: Application of Bayesian modelling with infliximab to determine optimal patient-specific regimens
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. E. Ritter*1, H. E. SarlesJr2, R. C. McLeay3, L. J. Van Anglen4, C. P. Schroeder4, T. C. Hardin4

Created: Friday, 22 February 2019, 9:41 AM
P339: Crohn’s disease and self-monitoring through a mobile App: The Medicrohn study
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Echarri1*, I. Vera2, J. Guardiola3, R. De Lucas2, V. Ollero1, B. Castro4, F. Gallego5, M. Aguas6, M. Chaparro7, C. Arajol3, P. Robledo8, D. Ceballos9, S. García10, S. Riestra11, I. Marín-Jimenez12, J. Muñiz13, P. Nos6

Created: Thursday, 21 February 2019, 9:14 AM
P339: Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: TheodorakiMD- MA- PhD c, E.(1);Orfanoudaki, E.(1);Foteinogiannopoulou, K.(1);Andreou, N.P.(2);Gazouli, M.(2);Koutroubakis, I.(1);
Created: Friday, 11 February 2022, 3:52 PM
P339: MadCAM1 expression in intestinal lamina propria endothelium varies among inflammatory bowel disease patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Zamborsky T.1,2, Berakova K.3, Kadleckova B.2, Podmanicky D.4, Zelinkova Z.*1

Created: Wednesday, 20 February 2019, 10:36 AM
P339: Pregnant women with perianal Crohn’s Disease: suggestions for the improvement of the current guideline on delivery method
Year: 2021
Source: ECCO'21 Virtual
Authors: Schaafsma, I.(1);Hoogenboom, F.(2);Visschedijk, M.(1);Prins, J.(3);Dijkstra, G.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P339: The efficacy of intravenous iron therapy in IBD patients with active disease is not influenced by the degree of inflammatory activity
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Walper*1, A. Dignass2, 3, J. Stein3, 4

Created: Friday, 22 February 2019, 9:49 AM
P339: Zonulin concentration in patients with ulcerative colitis with and without COVID-19 infection
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Knyazev, O.(1);Kulakov, D.(1)*;Kagramanova, A.(1);Tishaeva, I.(2);Baranova, T.(2);Poletova, A.(2);
Created: Friday, 14 July 2023, 11:05 AM
P340 Comorbidity is associated with safety outcomes in vedolizumab- and ustekinumab-treated inflammatory bowel disease patients
Year: 2020
Source: ECCO'20 Vienna
Authors: V. Asscher1, V. Biemans2,3, M. Pierik3, G. Dijkstra4, A. Van der Meulen-de Jong1, M. Löwenberg5, S. van der Marel6, N. de Boer7, A. Bodelier8, J. Jansen9, R. West10, J. Haans3, W. van Dop2, R. Weersma4, F. Hoentjen2, J. Maljaars1, on behalf of the Dutch Initiative on Crohn and Colitis (ICC)
Created: Thursday, 30 January 2020, 10:12 AM
Last Modified: Thursday, 24 February 2022, 4:23 PM by Dietrich Diz Angerer-GTN
P340: Issues on implementing treat-to-target approach in Asia Pacific, Middle East and Africa: Reality, gaps, and way forward -APMA IBD Coalition
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Akyüz, F.(1)*;An, Y.K.(2);Aniwan, S.(3);Bui, H.H.(4);Chan, W.P.(5);Choi, C.H.(6);Chopdat, N.(7);Connor, S.(8);Desai, D.(9);Flanagan, E.(10);Kobayashi, T.(11);Leong, R.W.(12);Leow, A.(13);Leung, W.K.(14);Limsrivilai, J.(15);Peddi, K.(16);Pribadi, R.R.(17);Ran, Z.(18);Wei, S.C.(19);Wu, K.(20);Ye, B.D.(21);
Created: Friday, 14 July 2023, 11:05 AM
P340: Postoperative clinical recurrence in Crohn’s disease patients: the Practicrohn study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

E. Domènech*1, V. García2, M. D. Martín Arranz3, M. Barreiro-de Acosta4, A. Gutiérrez5, L. Cea-Calvo6, C. Romero6, B. Juliá6

Created: Friday, 22 February 2019, 9:49 AM
P340: Prevalence and long-term effect of antiplatelet use in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Mantaka A., Renieri V., Koutroubakis I.

Created: Wednesday, 20 February 2019, 10:36 AM
P340: Real-world treatment patterns and recurrence rates of rectovaginal fistulas in patients with Crohn’s disease: A retrospective cohort database analysis
Year: 2021
Source: ECCO'21 Virtual
Authors: Karki, C.(1);Latremouille-Viau, D.(2);Gilaberte, I.(3);Hantsbarger, G.(4);Romdhani, H.(2);Lightner, A.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P340: Risankizumab in Inflammatory Bowel Disease: Real World Experience from a Pre-Approval Access Program
Year: 2021
Source: ECCO'22
Authors: Dawson, P.(1);Sharma, E.(1);Dart, R.J.(1);Lim, S.(1);Anderson, S.H.(1);Ray, S.(1);Mawdsley, J.(1);Irving, P.M.(1);Samaan, M.A.(1);
Created: Friday, 11 February 2022, 3:52 PM
Last Modified: Friday, 4 March 2022, 1:42 PM by Dietrich Diz Angerer-GTN
P340: Serum albumin and C-reactive protein week 2/week 0 ratio after anti-TNF therapy best predict both short- and long-term clinical outcomes in anti-TNF-naïve ulcerative colitis patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

S.-H. Lee1*, K. Chang1, E.M. Song1, S.W. Hwang1,2, S.H. Park1,2, D.-H. Yang1, J.-S. Byeon1, S.-J. Myung1, S.-K. Yang1,2, B.D. Ye1,2

Created: Thursday, 21 February 2019, 9:14 AM
P340: Vedolizumab in the treatment of chronic refractory pouchitis: a systematic review
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W-C. Lim*1, H. Lin1

Created: Friday, 22 February 2019, 9:41 AM
P341 Induction of response and remission: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Vickers1, A. Nag2, B. Devine3, B.E. Sands4, R. Panaccione5, L. Peyrin-Biroulet6, S. Danese7, S. Vermeire8, K.J. Gorelick9, M. Goetsch10, L. Hartley1

Created: Thursday, 30 January 2020, 10:12 AM
P341: Analytical performance of a new iPhone-based patient monitoring system comparable to ELISA for measuring faecal calprotectin in inflammatory bowel disease patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. F. Wintgens*1, A. A. Wulandari2, A. Dignass3, 4, F. Hartmann3, 4, J. Stein2, 3

Created: Friday, 22 February 2019, 9:49 AM
P341: Combination of corticosteroids and 5-aminosalycilates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: a global survey of physicians' practice
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ben-Horin S.*1,2, Andrews J.M.3, Katsanos K.H.4, Rieder F.5, Steinwurz F.6, Karmiris K.7, Cheon J.H.8, Moran G.W.9, Cesarini M.10, Stone C.D.11, Schwartz D.12, Protic M.13, Roblin X.14, Roda G.15, Chen M.2, Har-Noy O.1, Bernstein C.N.16

Created: Wednesday, 20 February 2019, 10:36 AM